Steroid-resistant	O
asthma	O
.	O

Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O

Patients	O
were	O
classified	O
as	O
steroid	O
sensitive	O
(	O
SS	O
)	O
if	O
their	O
morning	O
FEV1	O
increased	O
>	O
30	O
%	O
after	O
a	O
1-wk	O
course	O
of	O
oral	O
prednisone	O
20	O
mg	O
twice	O
daily	O
and	O
steroid	O
resistant	O
(	O
SR	O
)	O
if	O
they	O
failed	O
to	O
increase	O
>	O
15	O
%	O
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B-protein
binding	O
abnormalities	O
:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B-protein
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

This	O
defect	O
was	O
localized	O
to	O
T	B-cell_type
cells	I-cell_type
and	O
reverted	O
to	O
normal	O
after	O
48	O
h	O
in	O
culture	O
media	O
.	O

However	O
,	O
incubation	O
with	O
a	O
combination	O
of	O
IL-2	B-protein
and	O
IL-4	B-protein
sustained	O
this	O
abnormality	O
.	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B-protein
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
GR	B-protein
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B-protein
and	O
IL-4	B-protein
.	O

Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine	B-protein
-induced	O
reduction	O
in	O
GR	B-protein
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	B-protein
number	O
.	O

These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O

Steroid-resistant	NULL
Asthma	NULL
Cellular	NULL
Mechanisms	NULL
Contributing	NULL
to	NULL
inadequate	NULL
Response	NULL
to	NULL
Glucocorticoid	NULL
Therapy	NULL
Ellen	NULL
R.	NULL
Sher	NULL
,	NULL
*	NULL
Donald	NULL
Y.	NULL
M.	NULL
Leung	NULL
,	NULL
**	NULL
Wendy	NULL
Surs	NULL
,	NULL
*	NULL
Jeffrey	NULL
C.	NULL
Kam	NULL
,	NULL
*	NULL
George	NULL
Zieg	NULL
,	NULL
*	NULL
Alan	NULL
K.	NULL
Kamada	NULL
,	NULL
*	NULL
and	NULL
Stanley	NULL
J.	NULL
Szefler	NULL
***	NULL
``	NULL
Divisions	NULL
of	NULL
Allergy-Immunology	NULL
and	NULL
Clinical	NULL
Pharmacology	NULL
,	NULL
Departments	NULL
of	NULL
*	NULL
Pediatrics	NULL
and	NULL
*	NULL
Medicine	NULL
,	NULL
National	NULL
Jewish	NULL
Center	NULL
for	NULL
Immunology	NULL
and	NULL
Respiratory	NULL
Medicine	NULL
,	NULL
Denver	NULL
,	NULL
Colorado	NULL
80206	NULL
;	NULL
and	NULL
Departments	NULL
of	NULL
}	NULL
Pediatrics	NULL
and	NULL
Pharmacology	NULL
,	NULL
University	NULL
of	NULL
Colorado	NULL
Health	NULL
Sciences	NULL
Center	NULL
,	NULL
Denver	NULL
,	NULL
Colorado	NULL
80262	NULL
Abstract	NULL
The	NULL
current	NULL
study	NULL
examined	NULL
whether	NULL
alterations	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
binding	NULL
contribute	NULL
to	NULL
poor	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
in	NULL
asthma	NULL
.	NULL

29	NULL
asthma	NULL
patients	NULL
with	NULL
forced	NULL
expiratory	NULL
volume	NULL
in	NULL
1	NULL
s	NULL
(	NULL
FEV	NULL
,	NULL
)	NULL
<	NULL
70	NULL
%	NULL
predicted	NULL
were	NULL
stud-ied	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
as	NULL
steroid	NULL
sensitive	NULL
(	NULL
SS	NULL
)	NULL
if	NULL
their	NULL
morning	NULL
FEV	NULL
,	NULL
increased	NULL
>	NULL
30	NULL
%	NULL
after	NULL
a	NULL
1-wk	NULL
course	NULL
of	NULL
oral	NULL
prednisone	NULL
20	NULL
mg	NULL
twice	NULL
daily	NULL
and	NULL
steroid	NULL
resistant	NULL
(	NULL
SR	NULL
)	NULL
if	NULL
they	NULL
failed	NULL
to	NULL
increase	NULL
>	NULL
15	NULL
%	NULL
.	NULL

PBMC	NULL
obtained	NULL
from	NULL
these	NULL
two	NULL
groups	NULL
,	NULL
17	NULL
SR	NULL
and	NULL
12	NULL
SS	NULL
,	NULL
as	NULL
well	NULL
as	NULL
12	NULL
normal	NULL
controls	NULL
were	NULL
analyzed	NULL
.	NULL

SR	NULL
patients	NULL
had	NULL
two	NULL
distinguishable	NULL
GR	NULL
binding	NULL
abnormali-ties	NULL
:	NULL
15	NULL
of	NULL
the	NULL
17	NULL
SR	NULL
patients	NULL
demonstrated	NULL
a	NULL
significantly	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
SS	NULL
patients	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
and	NULL
normal	NULL
controls	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
.	NULL

This	NULL
defect	NULL
was	NULL
localized	NULL
to	NULL
T	NULL
cells	NULL
and	NULL
reverted	NULL
to	NULL
normal	NULL
after	NULL
48	NULL
h	NULL
in	NULL
culture	NULL
media	NULL
.	NULL

However	NULL
,	NULL
incubation	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
sustained	NULL
this	NULL
abnormality	NULL
.	NULL

The	NULL
other	NULL
two	NULL
SR	NULL
patients	NULL
had	NULL
an	NULL
abnormally	NULL
low	NULL
GR	NULL
number	NULL
with	NULL
normal	NULL
binding	NULL
affinity	NULL
that	NULL
was	NULL
not	NULL
limited	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
GR	NULL
number	NULL
failed	NULL
to	NULL
normalize	NULL
after	NULL
incubation	NULL
in	NULL
media	NULL
alone	NULL
or	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Therefore	NULL
,	NULL
SR	NULL
asthma	NULL
may	NULL
be	NULL
due	NULL
to	NULL
more	NULL
than	NULL
one	NULL
abnormal-ity	NULL
,	NULL
the	NULL
majority	NULL
related	NULL
to	NULL
a	NULL
reversible	NULL
cytokine-induced	NULL
reduction	NULL
in	NULL
GR	NULL
binding	NULL
affinity	NULL
and	NULL
the	NULL
second	NULL
related	NULL
to	NULL
an	NULL
irreversible	NULL
reduction	NULL
in	NULL
GR	NULL
number	NULL
.	NULL

These	NULL
findings	NULL
may	NULL
have	NULL
important	NULL
implications	NULL
for	NULL
the	NULL
design	NULL
of	NULL
alternative	NULL
treatment	NULL
approaches	NULL
for	NULL
recalcitrant	NULL
asthma	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1994	NULL
.	NULL

93:33-39	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
steroid-resistant	NULL
asthma	NULL
«	NULL
glucocorticoid	NULL
receptors	NULL
»	NULL
glucocorticoids	NULL
»	NULL
cytokines	NULL
«	NULL
immune	NULL
activation	NULL
Introduction	NULL
Recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
the	NULL
importance	NULL
of	NULL
airway	NULL
inflammation	NULL
and	NULL
immune	NULL
activation	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
asthma	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Glucocorticoids	NULL
are	NULL
the	NULL
most	NULL
potent	NULL
antiinflammatory	NULL
therapy	NULL
commonly	NULL
used	NULL
in	NULL
this	NULL
disease	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Certain	NULL
asthma	NULL
patients	NULL
,	NULL
however	NULL
,	NULL
fail	NULL
to	NULL
respond	NULL
to	NULL
combined	NULL
systemic	NULL
and	NULL
inhaled	NULL
glucocorticoid	NULL
treatment	NULL
despite	NULL
very	NULL
high	NULL
doses	NULL
over	NULL
extended	NULL
treatment	NULL
periods	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
Address	NULL
correspondence	NULL
to	NULL
Donald	NULL
Y.	NULL
M.	NULL
Leung	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Ph.D.	NULL
,	NULL
National	NULL
Jewish	NULL
Center	NULL
for	NULL
Immunology	NULL
and	NULL
Respiratory	NULL
Medicine	NULL
,	NULL
1400	NULL
Jackson	NULL
Street	NULL
,	NULL
Room	NULL
K926	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
80206	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
10	NULL
May	NULL
1993	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
13	NULL
August	NULL
1993	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
002	NULL
1-9738/94/01/0033/07	NULL
$	NULL
2.00	NULL
Volume	NULL
93	NULL
,	NULL
January	NULL
1994	NULL
,	NULL
33-39	NULL
patients	NULL
continue	NULL
treatment	NULL
with	NULL
glucocorticoids	NULL
despite	NULL
the	NULL
onset	NULL
of	NULL
serious	NULL
adverse	NULL
effects	NULL
and	NULL
poor	NULL
clinical	NULL
response	NULL
.	NULL

These	NULL
patients	NULL
require	NULL
alternative	NULL
approaches	NULL
to	NULL
treatment	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
important	NULL
to	NULL
understand	NULL
the	NULL
mechanisms	NULL
underlying	NULL
this	NULL
apparent	NULL
steroid	NULL
resistance	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
steroid-resistant	NULL
(	NULL
SR	NULL
)	NULL
'	NULL
asthma	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
failure	NULL
of	NULL
glucocorticoids	NULL
to	NULL
inhibit	NULL
their	NULL
in	NULL
vitro	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
secretion	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
of	NULL
SR	NULL
asthmatics	NULL
,	NULL
but	NULL
not	NULL
steroid-sensitive	NULL
(	NULL
SS	NULL
)	NULL
asthmatics	NULL
,	NULL
are	NULL
persistently	NULL
activated	NULL
despite	NULL
continued	NULL
treatment	NULL
with	NULL
aggressive	NULL
steroid	NULL
therapy	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Glucocorticoids	NULL
bind	NULL
to	NULL
a	NULL
specific	NULL
intracellular	NULL
receptor	NULL
to	NULL
inhibit	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
various	NULL
stimuli	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
possible	NULL
that	NULL
the	NULL
poor	NULL
glucocorticoid	NULL
response	NULL
in	NULL
SR	NULL
asthma	NULL
is	NULL
due	NULL
to	NULL
an	NULL
alteration	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
number	NULL
or	NULL
binding	NULL
affinity	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
PBMC	NULL
from	NULL
SR	NULL
asthmatics	NULL
to	NULL
determine	NULL
whether	NULL
abnormalities	NULL
in	NULL
GR	NULL
binding	NULL
may	NULL
contribute	NULL
to	NULL
their	NULL
inadequate	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

Methods	NULL
Patient	NULL
selection	NULL
.	NULL

Patients	NULL
with	NULL
a	NULL
diagnosis	NULL
of	NULL
asthma	NULL
,	NULL
based	NULL
on	NULL
American	NULL
Thoracic	NULL
Society	NULL
criteria	NULL
(	NULL
12	NULL
)	NULL
,	NULL
were	NULL
selected	NULL
for	NULL
evaluation	NULL
.	NULL

They	NULL
were	NULL
included	NULL
if	NULL
they	NULL
had	NULL
a	NULL
morning	NULL
prebronchodilator	NULL
forced	NULL
expiratory	NULL
volume	NULL
in	NULL
1	NULL
s	NULL
(	NULL
FEV	NULL
,	NULL
)	NULL
<	NULL
70	NULL
%	NULL
of	NULL
predicted	NULL
values	NULL
and	NULL
a	NULL
z	NULL
15	NULL
%	NULL
increase	NULL
in	NULL
FEV	NULL
,	NULL
after	NULL
two	NULL
inhalations	NULL
of	NULL
albuterol	NULL
(	NULL
90	NULL
ug	NULL
per	NULL
actua-tion	NULL
)	NULL
.	NULL

Patients	NULL
were	NULL
excluded	NULL
if	NULL
they	NULL
had	NULL
evidence	NULL
for	NULL
other	NULL
types	NULL
of	NULL
lung	NULL
disease	NULL
,	NULL
pregnancy	NULL
,	NULL
suspected	NULL
noncompliance	NULL
with	NULL
medical	NULL
care	NULL
.	NULL

or	NULL
concurrent	NULL
therapy	NULL
with	NULL
medications	NULL
that	NULL
alter	NULL
glucocorticoid	NULL
metab-olism	NULL
,	NULL
such	NULL
as	NULL
anticonvulsants	NULL
or	NULL
erythromycin	NULL
.	NULL

A	NULL
complete	NULL
set	NULL
of	NULL
pulmonary	NULL
function	NULL
tests	NULL
with	NULL
lung	NULL
volume	NULL
,	NULL
methacholine	NULL
bronchial	NULL
chal-lenge	NULL
,	NULL
and	NULL
diffusion	NULL
capacity	NULL
/	NULL
total	NULL
lung	NULL
capacity	NULL
ratio	NULL
were	NULL
obtained	NULL
if	NULL
the	NULL
diagnosis	NULL
of	NULL
asthma	NULL
required	NULL
confirmation	NULL
.	NULL

Informed	NULL
consent	NULL
.	NULL

approved	NULL
by	NULL
the	NULL
National	NULL
Jewish	NULL
Institutional	NULL
Review	NULL
Board	NULL
.	NULL

was	NULL
obtained	NULL
from	NULL
all	NULL
patients	NULL
before	NULL
their	NULL
entry	NULL
into	NULL
this	NULL
study	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
as	NULL
SS	NULL
or	NULL
SR	NULL
based	NULL
on	NULL
their	NULL
prebronchodilator	NULL
morning	NULL
FEV	NULL
,	NULL
and	NULL
their	NULL
response	NULL
to	NULL
a	NULL
course	NULL
of	NULL
oral	NULL
prednisone	NULL
.	NULL

Asthmatic	NULL
patients	NULL
were	NULL
defined	NULL
as	NULL
SR	NULL
if	NULL
they	NULL
failed	NULL
to	NULL
improve	NULL
their	NULL
morning	NULL
prebronchodilator	NULL
FEV	NULL
,	NULL
by	NULL
>	NULL
15	NULL
%	NULL
after	NULL
a	NULL
I-wk	NULL
course	NULL
of	NULL
prednisone	NULL
at	NULL
a	NULL
minimum	NULL
oral	NULL
dose	NULL
of	NULL
40	NULL
mg/d	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
as	NULL
SS	NULL
if	NULL
they	NULL
had	NULL
an	NULL
increase	NULL
in	NULL
baseline	NULL
FEV	NULL
,	NULL
of	NULL
30	NULL
%	NULL
or	NULL
greater	NULL
.	NULL

All	NULL
SR	NULL
asthma	NULL
patients	NULL
had	NULL
glucocorticoid	NULL
pharmacokinetic	NULL
studies	NULL
to	NULL
exclude	NULL
those	NULL
patients	NULL
with	NULL
an	NULL
abnormality	NULL
in	NULL
prednisone	NULL
absorption	NULL
or	NULL
metabolism	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Cell	NULL
isolation	NULL
.	NULL

Peripheral	NULL
blood	NULL
was	NULL
collected	NULL
in	NULL
heparinized	NULL
syringes	NULL
and	NULL
PBMC	NULL
were	NULL
isolated	NULL
by	NULL
gradient	NULL
centrifugation	NULL
(	NULL
Ficoll-Pa-que®	NULL
:	NULL
Pharmacia	NULL
LKB	NULL
Biotechnology	NULL
,	NULL
Inc..	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Further	NULL
isolation	NULL
for	NULL
the	NULL
T	NULL
cell	NULL
component	NULL
was	NULL
performed	NULL
by	NULL
sheep	NULL
red	NULL
cell	NULL
(	NULL
E	NULL
)	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
AP-1	NULL
,	NULL
activation	NULL
protein-1	NULL
;	NULL
FEV	NULL
,	NULL
,	NULL
forced	NULL
expiratory	NULL
volume	NULL
in	NULL
1s	NULL
;	NULL
GR	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
GRE	NULL
,	NULL
glucocorticoid-responsive	NULL
elements	NULL
:	NULL
SR	NULL
,	NULL
steroid	NULL
resistant	NULL
:	NULL
SS	NULL
,	NULL
steroid	NULL
sensitive	NULL
.	NULL

Mechanisms	NULL
of	NULL
Steroid-resistant	NULL
Asthma	NULL
__	NULL
33	NULL
rosetting	NULL
(	NULL
Colorado	NULL
Serum	NULL
Co.	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
)	NULL
,	NULL
and	NULL
the	NULL
(	NULL
E-	NULL
)	NULL
non-T	NULL
cell	NULL
population	NULL
was	NULL
purified	NULL
further	NULL
by	NULL
lysis	NULL
with	NULL
anti-CD3	NULL
(	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
,	NULL
Inc.	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
rabbit	NULL
complement	NULL
(	NULL
Gibco	NULL
Labs	NULL
.	NULL

,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

This	NULL
procedure	NULL
yielded	NULL
an	NULL
E	NULL
(	NULL
+	NULL
)	NULL
fraction	NULL
>	NULL
97	NULL
%	NULL
T	NULL
cell	NULL
purity	NULL
and	NULL
<	NULL
1	NULL
%	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
E	NULL
(	NULL
-	NULL
)	NULL
fraction	NULL
contained	NULL
<	NULL
5	NULL
%	NULL
T	NULL
cells	NULL
.	NULL

All	NULL
blood	NULL
samples	NULL
were	NULL
collected	NULL
between	NULL
7	NULL
and	NULL
8	NULL
a.m.	NULL
,	NULL
before	NULL
medications	NULL
and	NULL
at	NULL
least	NULL
24	NULL
h	NULL
after	NULL
any	NULL
oral	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

A	NULL
total	NULL
blood	NULL
sample	NULL
of	NULL
80	NULL
ml	NULL
was	NULL
required	NULL
for	NULL
a	NULL
standard	NULL
binding	NULL
assay	NULL
and	NULL
400	NULL
ml	NULL
for	NULL
assay	NULL
that	NULL
required	NULL
isolation	NULL
of	NULL
purified	NULL
T	NULL
cells	NULL
.	NULL

Glucocorticoid	NULL
receptor	NULL
binding	NULL
analysis	NULL
.	NULL

{	NULL
(	NULL
Amersham	NULL
Corp.	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
radioligand	NULL
binding	NULL
assay	NULL
and	NULL
Scatchard	NULL
analysis	NULL
,	NULL
based	NULL
on	NULL
the	NULL
method	NULL
of	NULL
Crabtree	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
measure	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
PBMC	NULL
from	NULL
normal	NULL
donors	NULL
and	NULL
asthma	NULL
patients	NULL
.	NULL

Cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Gibco	NULL
Labs	NULL
.	NULL
)	NULL

at	NULL
37°C	NULL
for	NULL
1	NULL
h	NULL
with	NULL
10	NULL
different	NULL
concentrations	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Jdexamethasone	NULL
in	NULL
duplicate	NULL
ranging	NULL
from	NULL
0.8	NULL
to	NULL
400	NULL
nM	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
1,000-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
dexamethasone	NULL
.	NULL

Measurements	NULL
of	NULL
glucocorticoid	NULL
bound	NULL
to	NULL
nuclear	NULL
receptors	NULL
were	NULL
obtained	NULL
by	NULL
hypotonic	NULL
lysis	NULL
of	NULL
one	NULL
set	NULL
of	NULL
PBMC	NULL
with	NULL
1.5	NULL
mM	NULL
MgCl	NULL
;	NULL
at	NULL
3°C	NULL
for	NULL
30	NULL
min	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
12,000	NULL
g	NULL
for	NULL
4	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
to	NULL
isolate	NULL
the	NULL
nuclear	NULL
fraction	NULL
for	NULL
radioligand	NULL
binding	NULL
analysis	NULL
.	NULL

Cytosolic	NULL
receptors	NULL
were	NULL
obtained	NULL
after	NULL
hypotonic	NULL
lysis	NULL
of	NULL
the	NULL
other	NULL
set	NULL
of	NULL
PBMC	NULL
with	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
containing	NULL
dextran-coated	NULL
charcoal	NULL
at	NULL
3°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
centrifuged	NULL
at	NULL
12,000	NULL
g	NULL
for	NULL
4	NULL
min	NULL
and	NULL
100	NULL
pl	NULL
of	NULL
supernatant	NULL
was	NULL
removed	NULL
for	NULL
cytosolic	NULL
receptor	NULL
binding	NULL
parameters	NULL
.	NULL

Analyzing	NULL
the	NULL
two	NULL
fractions	NULL
,	NULL
we	NULL
assumed	NULL
that	NULL
GR	NULL
binding	NULL
is	NULL
saturable	NULL
while	NULL
nonspecific	NULL
binding	NULL
is	NULL
nonsaturable	NULL
.	NULL

For	NULL
measurement	NULL
of	NULL
nonspecific	NULL
binding	NULL
,	NULL
a	NULL
single	NULL
measurement	NULL
with	NULL
a	NULL
solution	NULL
of	NULL
20	NULL
nM	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone	NULL
and	NULL
2	NULL
uM	NULL
of	NULL
unlabeled	NULL
dexamethasone	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
was	NULL
used	NULL
.	NULL

All	NULL
values	NULL
obtained	NULL
for	NULL
both	NULL
cytoplasmic	NULL
and	NULL
nuclear-bound	NULL
glucocorticoid	NULL
were	NULL
corrected	NULL
for	NULL
nonsaturable	NULL
binding	NULL
for	NULL
each	NULL
respective	NULL
concentration	NULL
.	NULL

Saturation	NULL
binding	NULL
analysis	NULL
was	NULL
performed	NULL
assuming	NULL
a	NULL
linear	NULL
binding	NULL
plot	NULL
of	NULL
the	NULL
bound	NULL
divided	NULL
by	NULL
the	NULL
free	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone	NULL
concentration	NULL
versus	NULL
the	NULL
amount	NULL
bound	NULL
and	NULL
extrapolating	NULL
to	NULL
the	NULL
amount	NULL
bound	NULL
at	NULL
an	NULL
infinite	NULL
free	NULL
hormone	NULL
concentration	NULL
.	NULL

A	NULL
least-squares	NULL
linear	NULL
regression	NULL
fit	NULL
was	NULL
used	NULL
to	NULL
define	NULL
the	NULL
binding	NULL
pa-rameters	NULL
,	NULL
specifically	NULL
,	NULL
receptor	NULL
sites	NULL
per	NULL
cell	NULL
and	NULL
binding	NULL
affinity	NULL
.	NULL

Reversibility	NULL
and	NULL
cytokine	NULL
incubation	NULL
protocols	NULL
.	NULL

PBMC	NULL
from	NULL
normal	NULL
donors	NULL
and	NULL
SR	NULL
asthma	NULL
patients	NULL
were	NULL
isolated	NULL
and	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
Labs	NULL
.	NULL
)	NULL

containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Hyclone	NULL
Labs	NULL
.	NULL

,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
IL-2	NULL
(	NULL
50	NULL
U/ml	NULL
;	NULL
Cetus	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
and/or	NULL
IL-4	NULL
(	NULL
50	NULL
U/	NULL
ml	NULL
;	NULL
gift	NULL
of	NULL
Dr.	NULL
Paul	NULL
Trotta	NULL
,	NULL
Schering-Plough	NULL
Research	NULL
Institute	NULL
,	NULL
Bloom-field	NULL
,	NULL
NJ	NULL
)	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

PBMC	NULL
were	NULL
then	NULL
analyzed	NULL
for	NULL
GR	NULL
binding	NULL
parameters	NULL
.	NULL

Results	NULL
Patient	NULL
characteristics	NULL
.	NULL

Patient	NULL
characteristics	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
I.	NULL
SR	NULL
and	NULL
SS	NULL
asthmatics	NULL
were	NULL
similar	NULL
for	NULL
all	NULL
parameters	NULL
with	NULL
two	NULL
exceptions	NULL
.	NULL

First	NULL
,	NULL
although	NULL
the	NULL
SR	NULL
asthmatics	NULL
had	NULL
a	NULL
higher	NULL
baseline	NULL
FEV	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.025	NULL
)	NULL
before	NULL
the	NULL
prednisone	NULL
course	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
SS	NULL
asthma	NULL
patients	NULL
,	NULL
their	NULL
FEV	NULL
,	NULL
after	NULL
treatment	NULL
with	NULL
prednisone	NULL
was	NULL
significantly	NULL
lower	NULL
than	NULL
SS	NULL
asthmatics	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
12	NULL
of	NULL
the	NULL
17	NULL
SR	NULL
asthma	NULL
patients	NULL
received	NULL
maintenance	NULL
oral	NULL
prednisone	NULL
(	NULL
mean	NULL
daily	NULL
dose	NULL
=	NULL
24	NULL
mg	NULL
)	NULL
at	NULL
the	NULL
time	NULL
of	NULL
their	NULL
GR	NULL
assay	NULL
as	NULL
compared	NULL
with	NULL
none	NULL
of	NULL
the	NULL
SS	NULL
asthma	NULL
patients	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
SR	NULL
patients	NULL
(	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
,	NULL
see	NULL
below	NULL
)	NULL
developed	NULL
cushingoid	NULL
features	NULL
during	NULL
prednisone	NULL
therapy	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
one	NULL
of	NULL
the	NULL
patients	NULL
subsequently	NULL
labeled	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
(	NULL
see	NULL
below	NULL
)	NULL
maintained	NULL
a	NULL
normal	NULL
plasma	NULL
cortisol	NULL
concentration	NULL
(	NULL
12	NULL
ug/dl	NULL
)	NULL
and	NULL
did	NULL
not	NULL
34	NULL
_	NULL
Sher	NULL
,	NULL
Leung	NULL
,	NULL
Surs	NULL
,	NULL
Kam	NULL
,	NULL
Zieg	NULL
,	NULL
Kamada	NULL
,	NULL
and	NULL
Szefler	NULL
Table	NULL
I	NULL
.	NULL

Patient	NULL
Characteristics	NULL
SS	NULL
Asthma	NULL
SR	NULL
Asthma	NULL
Parameter	NULL
Patients	NULL
Patients	NULL
Number	NULL
of	NULL
subjects	NULL
12	NULL
17	NULL
Age	NULL
(	NULL
yr	NULL
)	NULL
*	NULL
24	NULL
24	NULL
Sex	NULL
(	NULL
m/f	NULL
)	NULL
8/4	NULL
12/5	NULL
FEV	NULL
,	NULL
before	NULL
BD	NULL
(	NULL
percent	NULL
predicted	NULL
)	NULL
*	NULL
47	NULL
58	NULL
FEV	NULL
,	NULL
after	NULL
BD	NULL
(	NULL
percent	NULL
predicted	NULL
)	NULL
*	NULL
69	NULL
74	NULL
FEV	NULL
,	NULL
after	NULL
steroid	NULL
burst	NULL
82	NULL
57	NULL
Duration	NULL
of	NULL
asthma	NULL
(	NULL
yr	NULL
)	NULL
*	NULL
16	NULL
19	NULL
Inhaled	NULL
steroids	NULL
(	NULL
yes/no	NULL
)	NULL
6/6	NULL
14/3	NULL
Systemic	NULL
steroids	NULL
(	NULL
yes/no	NULL
)	NULL
0/12	NULL
12/5	NULL
Systemic	NULL
steroid	NULL
dose*	NULL
N/A	NULL
24	NULL
Atopy	NULL
(	NULL
positive/negative	NULL
)	NULL
11/1	NULL
16/1	NULL
*	NULL
Mean	NULL
value	NULL
of	NULL
patients	NULL
before	NULL
burst	NULL
.	NULL

*	NULL
Mean	NULL
daily	NULL
prednisone	NULL
dose	NULL
in	NULL
milligrams	NULL
.	NULL

BD	NULL
,	NULL
bronchodilator	NULL
dose	NULL
.	NULL

develop	NULL
cushingoid	NULL
features	NULL
despite	NULL
continuous	NULL
treatment	NULL
with	NULL
oral	NULL
prednisone	NULL
(	NULL
20	NULL
mg	NULL
daily	NULL
)	NULL
.	NULL

The	NULL
other	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patient	NULL
did	NULL
not	NULL
receive	NULL
maintenance	NULL
prednisone	NULL
therapy	NULL
because	NULL
of	NULL
poor	NULL
clinical	NULL
response	NULL
.	NULL

PBMC	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
parameters	NULL
in	NULL
steroid-resistant	NULL
asthma	NULL
patients	NULL
.	NULL

Representative	NULL
Scatchard	NULL
plots	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
from	NULL
PBMC	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone	NULL
radioligand	NULL
binding	NULL
data	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
SR	NULL
asthma	NULL
,	NULL
and	NULL
a	NULL
patient	NULL
with	NULL
SS	NULL
asthma	NULL
.	NULL

PBMC	NULL
GR	NULL
binding	NULL
parameters	NULL
were	NULL
examined	NULL
in	NULL
three	NULL
study	NULL
groups	NULL
:	NULL
17	NULL
SR	NULL
asthma	NULL
patients	NULL
,	NULL
12	NULL
SS	NULL
asthma	NULL
patients	NULL
,	NULL
and	NULL
12	NULL
normal	NULL
non-asthmatic	NULL
controls	NULL
.	NULL

Each	NULL
study	NULL
group	NULL
showed	NULL
distinctive	NULL
binding	NULL
patterns	NULL
for	NULL
their	NULL
respective	NULL
nuclear	NULL
GR	NULL
.	NULL

Nonspecific	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone	NULL
binding	NULL
was	NULL
low	NULL
in	NULL
all	NULL
three	NULL
study	NULL
groups	NULL
(	NULL
2.6+0.5	NULL
vs	NULL
5.2+1.6	NULL
vs	NULL
3.5+1.0	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
normals	NULL
,	NULL
SS	NULL
asthmatics	NULL
,	NULL
and	NULL
SR	NULL
asthmatics	NULL
)	NULL
and	NULL
no	NULL
significant	NULL
difference	NULL
(	NULL
P	NULL
=	NULL
0.2	NULL
,	NULL
ANOVA	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
nonspecific	NULL
binding	NULL
among	NULL
the	NULL
three	NULL
groups	NULL
.	NULL

0.08	NULL
0.06	NULL
8	NULL
SR	NULL
Asthma	NULL
patient	NULL
&	NULL
Kda=40	NULL
nM	NULL
&	NULL
_	NULL
0.04	NULL
Rn=16641	NULL
sites/cell	NULL
-	NULL
!	NULL

a	NULL
3	NULL
g	NULL
Rn=7046	NULL
sites/cell	NULL
0.02	NULL
Normal	NULL
Control	NULL
Kd=7.8	NULL
nM	NULL
Rn=2297	NULL
si	NULL
11	NULL
0.00	NULL
r	NULL
sites/ce	NULL
.	NULL

t	NULL
T	NULL
i	NULL
0	NULL
500	NULL
1000	NULL
1500	NULL
2000	NULL
2500	NULL
[	NULL
3H	NULL
]	NULL
Dexamethasone	NULL
bound	NULL
(	NULL
cpm	NULL
)	NULL
Figure	NULL
1	NULL
.	NULL

Scatchard	NULL
analysis	NULL
of	NULL
[	NULL
+H	NULL
]	NULL
dexamethasone	NULL
radioligand	NULL
binding	NULL
data	NULL
of	NULL
PBMC	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
,	NULL
an	NULL
SS	NULL
asthmatic	NULL
,	NULL
and	NULL
a	NULL
type	NULL
I	NULL
SR	NULL
asthmatic	NULL
.	NULL

Glucocorticoid	NULL
receptor	NULL
number	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
intercept	NULL
of	NULL
the	NULL
x	NULL
axis	NULL
and	NULL
is	NULL
normalized	NULL
for	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
and	NULL
the	NULL
dissociation	NULL
constant	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
reciprocal	NULL
of	NULL
the	NULL
linear	NULL
slope	NULL
.	NULL

80	NULL
.	NULL

r-	NULL
20000	NULL
m	NULL
®	NULL
No	NULL
steroids	NULL
m	NULL
m	NULL
0	NULL
Inhaled	NULL
steroids	NULL
alone	NULL
m	NULL
60	NULL
4	NULL
:	NULL
m	NULL
Oral	NULL
+	NULL
Inhaled	NULL
steroids	NULL
-	NULL
15000	NULL
=	NULL
o	NULL
O	NULL
Oral	NULL
steroids	NULL
alone	NULL
o	NULL
2	NULL
-	NULL
$	NULL
&	NULL
a	NULL
__	NULL
*	NULL
3	NULL
w	NULL
94	NULL
o	NULL
In	NULL
H	NULL
-	NULL
£10000	NULL
¢	NULL
Figure	NULL
2	NULL
.	NULL

The	NULL
GR	NULL
binding	NULL
parameters	NULL
of	NULL
12	NULL
E	NULL
$	NULL
a	NULL
E	NULL
normal	NULL
(	NULL
NL	NULL
)	NULL
controls	NULL
,	NULL
17	NULL
SR	NULL
asthma	NULL
patients	NULL
,	NULL
“	NULL
3°	NULL
_§_	NULL
8°	NULL
g	NULL
and	NULL
12	NULL
SS	NULL
asthma	NULL
patients	NULL
.	NULL

Normal	NULL
ranges	NULL
for	NULL
®	NULL
pA	NULL
o	NULL
g	NULL
o	NULL
[	NULL
5000	NULL
=	NULL
both	NULL
GR	NULL
parameters	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
o	NULL
5	NULL
i.	NULL
es	NULL
shaded	NULL
bar	NULL
.	NULL

The	NULL
solid	NULL
bar	NULL
indicates	NULL
the	NULL
mean	NULL
o	NULL
L	NULL
g	NULL
p	NULL
MECA	NULL
.	NULL

%	NULL
for	NULL
each	NULL
group	NULL
.	NULL

All	NULL
groups	NULL
were	NULL
significantly	NULL
t	NULL
t	NULL
T	NULL
t	NULL
T	NULL
T	NULL
0	NULL
H	NULL
a-NL	NULL
SS	NULL
_	NULL
SR-Type	NULL
I	NULL
SR-Type	NULL
II	NULL
NL	NULL
S	NULL
$	NULL
_	NULL
SR-TypeI	NULL
SR-Type	NULL
II	NULL
different	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
,	NULL
ANOVA	NULL
)	NULL
from	NULL
each	NULL
(	NULL
n=12	NULL
)	NULL
(	NULL
n=12	NULL
)	NULL
(	NULL
n=15	NULL
)	NULL
(	NULL
n=2	NULL
)	NULL
(	NULL
n=12	NULL
)	NULL
(	NULL
n=12	NULL
)	NULL
(	NULL
n=15	NULL
)	NULL
(	NULL
n=2	NULL
)	NULL
other	NULL
.	NULL

As	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
15	NULL
of	NULL
the	NULL
17	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
had	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
their	NULL
GR	NULL
K	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
a	NULL
decrease	NULL
in	NULL
binding	NULL
affinity	NULL
for	NULL
glucocorticoids	NULL
,	NULL
and	NULL
an	NULL
increased	NULL
GR	NULL
number	NULL
in	NULL
the	NULL
nuclear	NULL
fraction	NULL
of	NULL
their	NULL
PBMC	NULL
when	NULL
compared	NULL
with	NULL
normal	NULL
subjects	NULL
or	NULL
SS	NULL
asthma	NULL
patients	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
,	NULL
ANOVA	NULL
)	NULL
.	NULL

This	NULL
defect	NULL
was	NULL
designated	NULL
as	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
.	NULL

Two	NULL
other	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
had	NULL
normal	NULL
GR	NULL
K	NULL
,	NULL
values	NULL
but	NULL
a	NULL
markedly	NULL
decreased	NULL
number	NULL
of	NULL
GR	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
<	NULL
3	NULL
SD	NULL
below	NULL
the	NULL
normal	NULL
range	NULL
,	NULL
compared	NULL
with	NULL
all	NULL
other	NULL
groups	NULL
.	NULL

Both	NULL
patients	NULL
were	NULL
examined	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
maintenance	NULL
prednisone	NULL
therapy	NULL
.	NULL

This	NULL
defect	NULL
was	NULL
designated	NULL
as	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
SS	NULL
asthma	NULL
patients	NULL
also	NULL
had	NULL
a	NULL
decreased	NULL
GR	NULL
binding	NULL
affinity	NULL
as	NULL
compared	NULL
with	NULL
normals	NULL
.	NULL

Their	NULL
increased	NULL
GR	NULL
K	NULL
,	NULL
and	NULL
GR	NULL
number	NULL
were	NULL
significantly	NULL
less	NULL
than	NULL
those	NULL
observed	NULL
in	NULL
the	NULL
SR	NULL
asthma	NULL
group	NULL
but	NULL
significantly	NULL
more	NULL
than	NULL
the	NULL
normal	NULL
control	NULL
group	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
,	NULL
ANOVA	NULL
)	NULL
.	NULL

Patients	NULL
with	NULL
SR	NULL
asthma	NULL
or	NULL
SS	NULL
asthma	NULL
did	NULL
not	NULL
have	NULL
any	NULL
significant	NULL
abnormality	NULL
in	NULL
cytosolic	NULL
GR	NULL
K	NULL
,	NULL
or	NULL
GR	NULL
number	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Since	NULL
12	NULL
of	NULL
the	NULL
17	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
received	NULL
oral	NULL
prednisone	NULL
(	NULL
mean	NULL
daily	NULL
dose	NULL
=	NULL
24	NULL
mg	NULL
)	NULL
at	NULL
the	NULL
time	NULL
of	NULL
their	NULL
GR	NULL
assay	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
systemic	NULL
steroids	NULL
on	NULL
GR	NULL
binding	NULL
parameters	NULL
Table	NULL
II	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Binding	NULL
Parameters	NULL
Nuclear	NULL
Cytosolic	NULL
binding	NULL
sites	NULL
binding	NULL
sites	NULL
Study	NULL
group	NULL
K4	NULL
GR	NULL
K4	NULL
GR	NULL
nM	NULL
sites/cell	NULL
nM	NULL
sites/cell	NULL
Normal	NULL
controls	NULL
(	NULL
n	NULL
=	NULL
12	NULL
)	NULL
7.94+0.37*	NULL
2,514+173*	NULL
4.34+0.50	NULL
290+39	NULL
Asthma	NULL
patients	NULL
(	NULL
n	NULL
=	NULL
12	NULL
)	NULL
steroid	NULL
sensitive	NULL
21.6+2.10*	NULL
6,130+891*	NULL
Asthma	NULL
patients	NULL
(	NULL
n	NULL
=	NULL
15	NULL
)	NULL
steroid	NULL
resistant-type	NULL
I	NULL
Asthma	NULL
patients	NULL
(	NULL
n	NULL
=	NULL
2	NULL
)	NULL
steroid	NULL
resistant-type	NULL
II	NULL
8.53+2.13	NULL
460+124	NULL
42.1+3.07*	NULL
9,807+1146*	NULL
6.81+1.50	NULL
383+87	NULL
5.35+0.40	NULL
253+14	NULL
7.35+0.78	NULL
572+64	NULL
Values	NULL
are	NULL
+	NULL
SEM	NULL
.	NULL

*	NULL
Significantly	NULL
different	NULL
from	NULL
other	NULL
two	NULL
groups	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
,	NULL
ANOVA	NULL
)	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
were	NULL
not	NULL
included	NULL
in	NULL
statistical	NULL
analysis	NULL
.	NULL

was	NULL
examined	NULL
.	NULL

Three	NULL
approaches	NULL
were	NULL
used	NULL
.	NULL

First	NULL
,	NULL
we	NULL
measured	NULL
GR	NULL
binding	NULL
parameters	NULL
of	NULL
PBMC	NULL
from	NULL
five	NULL
SS	NULL
asthma	NULL
patients	NULL
before	NULL
and	NULL
immediately	NULL
after	NULL
a	NULL
1-wk	NULL
course	NULL
of	NULL
20	NULL
mg	NULL
twice	NULL
daily	NULL
prednisone	NULL
.	NULL

No	NULL
significant	NULL
changes	NULL
occurred	NULL
in	NULL
either	NULL
GR	NULL
number	NULL
(	NULL
P	NULL
=	NULL
0.26	NULL
)	NULL
or	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.31	NULL
)	NULL
after	NULL
this	NULL
1-wk	NULL
course	NULL
of	NULL
high	NULL
dose	NULL
oral	NULL
prednisone	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
we	NULL
assayed	NULL
PBMC	NULL
from	NULL
seven	NULL
patients	NULL
who	NULL
were	NULL
on	NULL
3-12	NULL
mo	NULL
of	NULL
20-100	NULL
mg	NULL
prednisone	NULL
daily	NULL
for	NULL
treatment	NULL
of	NULL
other	NULL
diseases	NULL
associated	NULL
with	NULL
tissue	NULL
inflammation	NULL
(	NULL
multiple	NULL
sclerosis	NULL
[	NULL
n	NULL
=	NULL
1	NULL
]	NULL
,	NULL
pulmonary	NULL
berylliosis	NULL
[	NULL
n	NULL
=	NULL
3	NULL
]	NULL
,	NULL
nummular	NULL
eczema	NULL
[	NULL
n	NULL
=	NULL
1	NULL
]	NULL
,	NULL
chronic	NULL
obstructive	NULL
pulmonary	NULL
disease	NULL
[	NULL
n=	NULL
1	NULL
]	NULL
,	NULL
and	NULL
interstitial	NULL
lung	NULL
disease	NULL
[	NULL
n=	NULL
1	NULL
]	NULL
)	NULL
.	NULL

None	NULL
of	NULL
these	NULL
patients	NULL
showed	NULL
the	NULL
degree	NULL
of	NULL
GR	NULL
abnormality	NULL
observed	NULL
in	NULL
the	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

The	NULL
GR	NULL
number	NULL
(	NULL
5,591+361	NULL
)	NULL
and	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
22.9+1.40	NULL
)	NULL
of	NULL
these	NULL
seven	NULL
patients	NULL
were	NULL
comparable	NULL
with	NULL
those	NULL
of	NULL
SS	NULL
asthma	NULL
patients	NULL
and	NULL
were	NULL
significantly	NULL
less	NULL
than	NULL
the	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
there	NULL
was	NULL
any	NULL
difference	NULL
in	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
who	NULL
did	NULL
or	NULL
did	NULL
not	NULL
receive	NULL
maintenance	NULL
oral	NULL
prednisone	NULL
therapy	NULL
.	NULL

Four	NULL
of	NULL
the	NULL
type	NULL
I	NULL
SR	NULL
asthmatics	NULL
were	NULL
not	NULL
taking	NULL
oral	NULL
steroids	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Their	NULL
PBMC	NULL
still	NULL
exhibited	NULL
the	NULL
same	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
40.8	NULL
nM	NULL
)	NULL
as	NULL
the	NULL
other	NULL
11	NULL
type	NULL
I	NULL
SR	NULL
asthmatics	NULL
(	NULL
GR	NULL
K	NULL
,	NULL
=	NULL
42.6	NULL
nM	NULL
)	NULL
who	NULL
received	NULL
maintenance	NULL
oral	NULL
prednisone	NULL
therapy	NULL
.	NULL

All	NULL
of	NULL
the	NULL
above	NULL
suggest	NULL
that	NULL
the	NULL
significantly	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
is	NULL
not	NULL
induced	NULL
by	NULL
glucocor-ticord	NULL
therapy	NULL
.	NULL

.	NULL

Localization	NULL
of	NULL
GR	NULL
binding	NULL
affinity	NULL
defect	NULL
to	NULL
T	NULL
cells	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
altered	NULL
GR	NULL
binding	NULL
parameters	NULL
were	NULL
restricted	NULL
to	NULL
specific	NULL
subsets	NULL
of	NULL
mononuclear	NULL
cells	NULL
in	NULL
the	NULL
two	NULL
subtypes	NULL
of	NULL
SR	NULL
asthma	NULL
patients	NULL
,	NULL
we	NULL
analyzed	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
their	NULL
T	NULL
cell	NULL
and	NULL
non-T	NULL
cell	NULL
30	NULL
p=0.31	NULL
p=0.26	NULL
10000	NULL
®	NULL
/	NULL
so00	NULL
7	NULL
26	NULL
C	NULL
e	NULL
--	NULL
--	NULL
--	NULL
-*	NULL
8	NULL
/	NULL
E	NULL
=	NULL
sono	NULL
&	NULL
E	NULL
20	NULL
®	NULL
--	NULL
--	NULL
--	NULL
-e	NULL
a	NULL
3	NULL
o	NULL
a00o	NULL
-	NULL
2.	NULL
in	NULL
¢	NULL
1s	NULL
A	NULL
E	NULL
2000	NULL
10	NULL
-	NULL
r	NULL
+	NULL
Baseline	NULL
Post	NULL
burst	NULL
Baseline	NULL
Post	NULL
burst	NULL
Figure	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
a	NULL
1-wk	NULL
course	NULL
of	NULL
oral	NULL
prednisone	NULL
,	NULL
40	NULL
mg/day	NULL
,	NULL
on	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
five	NULL
steroid-sensitive	NULL
asthma	NULL
patients	NULL
.	NULL

None	NULL
of	NULL
the	NULL
steroid-sensitive	NULL
asthma	NULL
patients	NULL
were	NULL
receiving	NULL
maintenance	NULL
oral	NULL
prednisone	NULL
therapy	NULL
before	NULL
evaluation	NULL
.	NULL

Mechanisms	NULL
of	NULL
Steroid-resistant	NULL
Asthma	NULL
__	NULL
35	NULL
subpopulations	NULL
.	NULL

A	NULL
fourfold	NULL
significant	NULL
increase	NULL
(	NULL
P	NULL
=	NULL
0.0009	NULL
)	NULL
in	NULL
T	NULL
cell	NULL
nuclear	NULL
GR	NULL
K	NULL
,	NULL
over	NULL
non-T	NULL
cells	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
population	NULL
of	NULL
type	NULL
1	NULL
SR	NULL
asthma	NULL
patients	NULL
as	NULL
compared	NULL
with	NULL
a	NULL
small	NULL
but	NULL
significantly	NULL
(	NULL
P	NULL
=	NULL
0.02	NULL
)	NULL
greater	NULL
T	NULL
cell	NULL
nuclear	NULL
GR	NULL
K	NULL
,	NULL
over	NULL
non-T	NULL
cells	NULL
in	NULL
normal	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
4	NULL
)	NULL
.	NULL

The	NULL
T	NULL
cells	NULL
from	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
also	NULL
had	NULL
a	NULL
significantly	NULL
higher	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
and	NULL
GR	NULL
number	NULL
(	NULL
P	NULL
=	NULL
0.046	NULL
)	NULL
than	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
controls	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
abnormally	NULL
low	NULL
GR	NULL
number	NULL
observed	NULL
in	NULL
a	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patient	NULL
was	NULL
not	NULL
limited	NULL
to	NULL
T	NULL
cells	NULL
but	NULL
was	NULL
also	NULL
present	NULL
in	NULL
non-T	NULL
cells	NULL
as	NULL
well	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

Insufficient	NULL
cells	NULL
were	NULL
available	NULL
from	NULL
the	NULL
second	NULL
type	NULL
II	NULL
SR	NULL
asthmatic	NULL
for	NULL
mononuclear	NULL
cell	NULL
subset	NULL
analysis	NULL
.	NULL

Effect	NULL
of	NULL
in	NULL
vitro	NULL
incubation	NULL
on	NULL
PBMC	NULL
GR	NULL
from	NULL
SR	NULL
asth-matics	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
alterations	NULL
in	NULL
PBMC	NULL
GR	NULL
binding	NULL
parameters	NULL
from	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
were	NULL
revers-ible	NULL
,	NULL
GR	NULL
binding	NULL
was	NULL
measured	NULL
before	NULL
and	NULL
after	NULL
incubation	NULL
of	NULL
PBMC	NULL
in	NULL
culture	NULL
medium	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

When	NULL
PBMC	NULL
from	NULL
five	NULL
patients	NULL
with	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
were	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
they	NULL
showed	NULL
a	NULL
significant	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
change	NULL
in	NULL
GR	NULL
binding	NULL
with	NULL
normalization	NULL
of	NULL
both	NULL
GR	NULL
K	NULL
,	NULL
and	NULL
GR	NULL
number	NULL
after	NULL
48	NULL
h	NULL
of	NULL
incubation	NULL
as	NULL
compared	NULL
with	NULL
values	NULL
after	NULL
immediate	NULL
analysis	NULL
.	NULL

Incubation	NULL
of	NULL
PBMC	NULL
from	NULL
seven	NULL
normal	NULL
donors	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
under	NULL
similar	NULL
culture	NULL
conditions	NULL
did	NULL
not	NULL
result	NULL
in	NULL
any	NULL
significant	NULL
change	NULL
in	NULL
either	NULL
GR	NULL
K	NULL
,	NULL
or	NULL
GR	NULL
number	NULL
.	NULL

These	NULL
data	NULL
support	NULL
the	NULL
concept	NULL
that	NULL
the	NULL
GR	NULL
binding	NULL
alterations	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
were	NULL
acquired	NULL
.	NULL

Since	NULL
asthma	NULL
is	NULL
associated	NULL
with	NULL
increased	NULL
immune	NULL
activation	NULL
and	NULL
cytokine	NULL
secretion	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
,	NULL
two	NULL
cytokines	NULL
reported	NULL
to	NULL
be	NULL
increased	NULL
in	NULL
asthma	NULL
(	NULL
16	NULL
)	NULL
,	NULL
on	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
patients	NULL
with	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
and	NULL
normal	NULL
donors	NULL
.	NULL

When	NULL
normal	NULL
PBMC	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
,	NULL
a	NULL
significant	NULL
increase	NULL
was	NULL
observed	NULL
both	NULL
in	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
and	NULL
in	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
sites	NULL
per	NULL
cell	NULL
(	NULL
P	NULL
=	NULL
0.001	NULL
)	NULL
at	NULL
48	NULL
h	NULL
as	NULL
compared	NULL
with	NULL
values	NULL
after	NULL
immediate	NULL
analysis	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
in	NULL
PBMC	NULL
from	NULL
type	NULL
I	NULL
SR	NULL
asthmatics	NULL
was	NULL
sustained	NULL
in	NULL
culture	NULL
over	NULL
the	NULL
48-h	NULL
period	NULL
when	NULL
their	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
incubation	NULL
of	NULL
normal	NULL
PBMC	NULL
with	NULL
IL-1	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
interferon-y	NULL
for	NULL
48	NULL
h	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
culture	NULL
medium	NULL
alone	NULL
,	NULL
did	NULL
not	NULL
induce	NULL
a	NULL
significant	NULL
elevation	NULL
in	NULL
GR	NULL
K	NULL
,	NULL
.	NULL

Based	NULL
on	NULL
a	NULL
minimum	NULL
of	NULL
three	NULL
experiments	NULL
,	NULL
mean+SEM	NULL
,	NULL
GR	NULL
K	NULL
,	NULL
after	NULL
incubation	NULL
A	NULL
W	NULL
T	NULL
cells	NULL
B	NULL
E1	NULL
Non	NULL
T	NULL
cells	NULL
p=	NULL
0.0001	NULL
—I	NULL
30	NULL
p=	NULL
0.046	NULL
—	NULL
]	NULL
20	NULL
4	NULL
Kd	NULL
(	NULL
nM	NULL
)	NULL
Normal	NULL
Controls	NULL
SR	NULL
Asthma	NULL
Type	NULL
I	NULL
SR	NULL
Asthma	NULL
Type	NULL
II	NULL
Normal	NULL
Controls	NULL
(	NULL
n=4	NULL
)	NULL
(	NULL
n=5	NULL
)	NULL
(	NULL
n=1	NULL
)	NULL
(	NULL
{	NULL
n=4	NULL
)	NULL
(	NULL
m=8	NULL
)	NULL
36	NULL
Sher	NULL
,	NULL
Leung	NULL
,	NULL
Surs	NULL
,	NULL
Kam	NULL
,	NULL
Zieg	NULL
,	NULL
Kamada	NULL
,	NULL
and	NULL
Szefler	NULL
SR	NULL
Asthma	NULL
Type	NULL
I	NULL
with	NULL
medium	NULL
alone	NULL
was	NULL
7.6+0.4	NULL
,	NULL
after	NULL
IL-1	NULL
was	NULL
3.6+1.2	NULL
,	NULL
after	NULL
IL-5	NULL
was	NULL
9.1+0.7	NULL
,	NULL
and	NULL
after	NULL
interferon	NULL
y	NULL
was	NULL
6.2+0.4	NULL
.	NULL

We	NULL
also	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
in	NULL
vitro	NULL
48-h	NULL
incubation	NULL
with	NULL
media	NULL
alone	NULL
and	NULL
with	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
on	NULL
the	NULL
two	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
with	NULL
low	NULL
GR	NULL
number	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
with	NULL
elevated	NULL
GR	NULL
K	NULL
,	NULL
and	NULL
GR	NULL
number	NULL
,	NULL
PBMC	NULL
from	NULL
these	NULL
two	NULL
patients	NULL
did	NULL
not	NULL
demonstrate	NULL
any	NULL
changes	NULL
in	NULL
GR	NULL
binding	NULL
when	NULL
incubated	NULL
in	NULL
culture	NULL
medium	NULL
alone	NULL
.	NULL

Furthermore	NULL
,	NULL
although	NULL
the	NULL
combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
increased	NULL
the	NULL
number	NULL
of	NULL
GRs	NULL
in	NULL
normal	NULL
PBMC	NULL
,	NULL
these	NULL
cytokines	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
GR	NULL
binding	NULL
parameters	NULL
from	NULL
these	NULL
two	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
low	NULL
GR	NULL
number	NULL
in	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
is	NULL
a	NULL
primary	NULL
irreversible	NULL
defect	NULL
,	NULL
whereas	NULL
the	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
is	NULL
an	NULL
acquired	NULL
reversible	NULL
defect	NULL
.	NULL

Discussion	NULL
Recent	NULL
proposed	NULL
guidelines	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
asthma	NULL
focus	NULL
on	NULL
early	NULL
intervention	NULL
with	NULL
antiinflammatory	NULL
therapy	NULL
,	NULL
especially	NULL
inhaled	NULL
glucocorticoids	NULL
(	NULL
3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
subset	NULL
of	NULL
asthma	NULL
patients	NULL
fails	NULL
to	NULL
demonstrate	NULL
a	NULL
satisfactory	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
recognize	NULL
these	NULL
patients	NULL
early	NULL
because	NULL
failure	NULL
to	NULL
respond	NULL
often	NULL
leads	NULL
to	NULL
courses	NULL
of	NULL
very	NULL
high	NULL
dose	NULL
glucocorticoid	NULL
therapy	NULL
and	NULL
consequent	NULL
adverse	NULL
effects	NULL
despite	NULL
persistent	NULL
airway	NULL
compromise	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
documented	NULL
rise	NULL
in	NULL
asthma	NULL
mortality	NULL
during	NULL
the	NULL
past	NULL
decade	NULL
despite	NULL
the	NULL
use	NULL
of	NULL
glucocorticoids	NULL
for	NULL
asthma	NULL
therapy	NULL
in	NULL
many	NULL
countries	NULL
raises	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
a	NULL
proportion	NULL
of	NULL
these	NULL
patients	NULL
was	NULL
indeed	NULL
steroid	NULL
resistant	NULL
.	NULL

Since	NULL
these	NULL
patients	NULL
likely	NULL
evolve	NULL
over	NULL
time	NULL
,	NULL
understanding	NULL
mechanisms	NULL
involved	NULL
in	NULL
glucocorticoid	NULL
resistance	NULL
could	NULL
lead	NULL
to	NULL
earlier	NULL
identification	NULL
and	NULL
could	NULL
provide	NULL
insight	NULL
for	NULL
new	NULL
directions	NULL
in	NULL
management	NULL
.	NULL

After	NULL
careful	NULL
clinical	NULL
assessment	NULL
for	NULL
poor	NULL
response	NULL
,	NULL
such	NULL
as	NULL
other	NULL
pulmonary	NULL
abnormalities	NULL
,	NULL
poor	NULL
technique	NULL
or	NULL
adherence	NULL
to	NULL
medication	NULL
schedules	NULL
,	NULL
pharmacokinetic	NULL
abnormalities	NULL
in	NULL
medication	NULL
absorption	NULL
,	NULL
distribution	NULL
,	NULL
or	NULL
elimination	NULL
,	NULL
and	NULL
concomitant	NULL
medical	NULL
or	NULL
psychological	NULL
disorders	NULL
,	NULL
questions	NULL
may	NULL
be	NULL
raised	NULL
whether	NULL
persistent	NULL
airway	NULL
inflammation	NULL
itself	NULL
or	NULL
genetic	NULL
abnormalities	NULL
in	NULL
GR	NULL
binding	NULL
contributes	NULL
to	NULL
poor	NULL
glucocorticoid	NULL
response	NULL
.	NULL

Earlier	NULL
studies	NULL
have	NULL
investigated	NULL
potential	NULL
mech-	NULL
Figure	NULL
4	NULL
.	NULL

The	NULL
GR	NULL
number	NULL
and	NULL
binding	NULL
affinity	NULL
were	NULL
measured	NULL
in	NULL
fractionated	NULL
T	NULL
and	NULL
non-T	NULL
cell	NULL
populations	NULL
.	NULL

The	NULL
increased	NULL
K	NULL
,	NULL
and	NULL
receptor	NULL
sites	NULL
per	NULL
cell	NULL
of	NULL
nuclear	NULL
GR	NULL
are	NULL
limited	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
population	NULL
of	NULL
SR	NULL
asthma	NULL
patients	NULL
and	NULL
are	NULL
significantly	NULL
different	NULL
from	NULL
normal	NULL
controls	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
K	NULL
,	NULL
;	NULL
P	NULL
=	NULL
0.046	NULL
GR	NULL
sites/cell	NULL
)	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
nuclear	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
the	NULL
non-T	NULL
ﬁx	NULL
?	NULL

“	NULL
cell	NULL
fraction	NULL
was	NULL
observed	NULL
.	NULL

Each	NULL
bar	NULL
(	NULL
m=1	NULL
)	NULL
represents	NULL
the	NULL
mean+SEM	NULL
.	NULL

tl2o/sauns	NULL
so03dada1	NULL
Glucocorticoid	NULL
receptor	NULL
binding	NULL
affinity	NULL
*	NULL
EH	NULL
Normal	NULL
controls	NULL
(	NULL
n=7	NULL
)	NULL
40	NULL
{	NULL
EZ	NULL
SR	NULL
Asthma-Type	NULL
I	NULL
(	NULL
n=5	NULL
)	NULL
CJ	NULL
SR	NULL
Asthma-Type	NULL
II	NULL
(	NULL
n=2	NULL
)	NULL
g	NULL
30	NULL
{	NULL
G	NULL
p	NULL
)	NULL
(	NULL
¥7	NULL
20	NULL
{	NULL
10	NULL
{	NULL
0	NULL
-	NULL
®	NULL
Time	NULL
of	NULL
incubation	NULL
(	NULL
hr	NULL
)	NULL
:	NULL
0	NULL
48	NULL
48	NULL
Treatment	NULL
:	NULL
-	NULL
Medium	NULL
Medium	NULL
Medium+IL2,4	NULL
20000	NULL
Glucocorticoid	NULL
receptor	NULL
number	NULL
EH	NULL
-	NULL
Normal	NULL
controls	NULL
(	NULL
n=7	NULL
)	NULL
#	NULL
EZ	NULL
SR	NULL
Asthma-Type	NULL
I	NULL
(	NULL
n=5	NULL
)	NULL
15000	NULL
4	NULL
CJ	NULL
SR	NULL
Asthma-Type	NULL
II	NULL
(	NULL
n=2	NULL
)	NULL
D	NULL
J	NULL
w	NULL
D	NULL
t	NULL
an	NULL
w	NULL
10000	NULL
4	NULL
w	NULL
CL	NULL
I	NULL
J	NULL
D	NULL
h	NULL
5000	NULL
4	NULL
0	NULL
{	NULL
``	NULL
3	NULL
Time	NULL
of	NULL
incubation	NULL
(	NULL
hr	NULL
)	NULL
:	NULL
0	NULL
48	NULL
48	NULL
Treatment	NULL
:	NULL
-	NULL
Medium	NULL
Medium	NULL
Medium+IL2,4	NULL
Figure	NULL
5	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
nuclear	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
PBMC	NULL
from	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
and	NULL
normal	NULL
donors	NULL
.	NULL

Freshly	NULL
isolated	NULL
PBMC	NULL
from	NULL
five	NULL
type	NULL
I	NULL
SR	NULL
asthmatics	NULL
(	NULL
time	NULL
0	NULL
hours	NULL
)	NULL
have	NULL
significantly	NULL
elevated	NULL
GR	NULL
K	NULL
,	NULL
(	NULL
*P	NULL
=	NULL
0.0001	NULL
)	NULL
and	NULL
GR	NULL
numbers	NULL
(	NULL
*P	NULL
=	NULL
0.002	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
normals	NULL
and	NULL
revert	NULL
to	NULL
normal	NULL
GR	NULL
binding	NULL
parameters	NULL
when	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
for	NULL
48	NULL
h.	NULL
Incubation	NULL
of	NULL
PBMC	NULL
from	NULL
seven	NULL
normal	NULL
subjects	NULL
and	NULL
two	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
shows	NULL
no	NULL
change	NULL
in	NULL
GR	NULL
binding	NULL
parameters	NULL
when	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
for	NULL
48	NULL
h.	NULL
Combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
significantly	NULL
increases	NULL
GR	NULL
K	NULL
,	NULL
and	NULL
GR	NULL
number	NULL
(	NULL
P	NULL
=	NULL
0.0001	NULL
)	NULL
of	NULL
normal	NULL
donors	NULL
and	NULL
alters	NULL
GR	NULL
binding	NULL
parameters	NULL
in	NULL
PBMC	NULL
from	NULL
type	NULL
I	NULL
SR	NULL
asthmatics	NULL
but	NULL
not	NULL
from	NULL
type	NULL
II	NULL
SR	NULL
asthmatic	NULL
patients	NULL
.	NULL

Each	NULL
bar	NULL
represents	NULL
the	NULL
mean+SEM	NULL
.	NULL

anisms	NULL
for	NULL
glucocorticoid	NULL
resistance	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Corrigan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
7	NULL
)	NULL
demonstrated	NULL
that	NULL
PHA-induced	NULL
proliferation	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
dexamethasone	NULL
in	NULL
SS	NULL
asthma	NULL
patients	NULL
but	NULL
not	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

They	NULL
also	NULL
demonstrated	NULL
that	NULL
dexamethasone	NULL
inhibits	NULL
IL-2	NULL
and	NULL
interferon-gamma	NULL
production	NULL
in	NULL
cells	NULL
from	NULL
SS	NULL
asthma	NULL
patients	NULL
but	NULL
not	NULL
in	NULL
cells	NULL
from	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
possibility	NULL
that	NULL
alterations	NULL
in	NULL
GR	NULL
binding	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
apparent	NULL
refractoriness	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

Our	NULL
operational	NULL
definition	NULL
of	NULL
SR	NULL
asthma	NULL
was	NULL
the	NULL
failure	NULL
to	NULL
improve	NULL
morning	NULL
prebronchodilator	NULL
FEV	NULL
,	NULL
by	NULL
>	NULL
15	NULL
%	NULL
after	NULL
a	NULL
1-wk	NULL
course	NULL
of	NULL
prednisone	NULL
at	NULL
a	NULL
minimum	NULL
oral	NULL
dose	NULL
of	NULL
40	NULL
mg/d	NULL
.	NULL

This	NULL
definition	NULL
was	NULL
based	NULL
on	NULL
our	NULL
previous	NULL
observation	NULL
that	NULL
over	NULL
90	NULL
%	NULL
of	NULL
asthmatics	NULL
show	NULL
a	NULL
>	NULL
15	NULL
%	NULL
improvement	NULL
in	NULL
their	NULL
morning	NULL
prebronchodilator	NULL
FEV	NULL
;	NULL
within	NULL
1	NULL
wk	NULL
of	NULL
oral	NULL
prednisone	NULL
(	NULL
40	NULL
mg	NULL
daily	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

We	NULL
limited	NULL
the	NULL
course	NULL
of	NULL
prednisone	NULL
to	NULL
1	NULL
wk	NULL
so	NULL
we	NULL
could	NULL
simultaneously	NULL
examine	NULL
a	NULL
group	NULL
of	NULL
SS	NULL
asthma	NULL
patients	NULL
on	NULL
a	NULL
similar	NULL
time	NULL
course	NULL
of	NULL
prednisone	NULL
therapy	NULL
.	NULL

Our	NULL
observations	NULL
indicate	NULL
that	NULL
there	NULL
are	NULL
at	NULL
least	NULL
two	NULL
mechanisms	NULL
present	NULL
in	NULL
this	NULL
population	NULL
of	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

Type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
have	NULL
an	NULL
abnormally	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
and	NULL
an	NULL
increased	NULL
number	NULL
of	NULL
receptor	NULL
sites	NULL
per	NULL
cell	NULL
compared	NULL
with	NULL
our	NULL
normal	NULL
population	NULL
and	NULL
our	NULL
SS	NULL
asthma	NULL
patients	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
defect	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
PBMC	NULL
GR	NULL
binding	NULL
is	NULL
limited	NULL
to	NULL
th	NULL
:	NULL
-	NULL
cell	NULL
population	NULL
.	NULL

Conversely	NULL
,	NULL
SR	NULL
asthma	NULL
patients	NULL
with	NULL
the	NULL
type	NULL
II	NULL
binding	NULL
abnormality	NULL
have	NULL
normal	NULL
binding	NULL
affinity	NULL
with	NULL
a	NULL
markedly	NULL
reduced	NULL
number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
per	NULL
cell	NULL
.	NULL

An	NULL
important	NULL
distinction	NULL
between	NULL
these	NULL
two	NULL
types	NULL
of	NULL
SR	NULL
asthma	NULL
was	NULL
that	NULL
the	NULL
GR	NULL
defect	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
was	NULL
reversible	NULL
in	NULL
culture	NULL
but	NULL
was	NULL
sustained	NULL
with	NULL
the	NULL
coincubation	NULL
of	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
binding	NULL
defect	NULL
in	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
was	NULL
irreversible	NULL
and	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
coincubation	NULL
with	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
PBMC	NULL
GR	NULL
defect	NULL
in	NULL
this	NULL
latter	NULL
form	NULL
of	NULL
SR	NULL
asthma	NULL
was	NULL
not	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

An	NULL
obvious	NULL
question	NULL
is	NULL
whether	NULL
the	NULL
abnormalities	NULL
in	NULL
GR	NULL
binding	NULL
parameters	NULL
observed	NULL
in	NULL
our	NULL
patients	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
systemic	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

Several	NULL
observations	NULL
suggest	NULL
that	NULL
this	NULL
is	NULL
not	NULL
a	NULL
relevant	NULL
mechanism	NULL
.	NULL

Specifically	NULL
,	NULL
we	NULL
ob-served	NULL
:	NULL
(	NULL
a	NULL
)	NULL
no	NULL
significant	NULL
change	NULL
in	NULL
GR	NULL
binding	NULL
parameters	NULL
after	NULL
1	NULL
wk	NULL
of	NULL
high	NULL
dose	NULL
``	NULL
burst	NULL
``	NULL
prednisone	NULL
in	NULL
five	NULL
SS	NULL
asthma	NULL
patients	NULL
who	NULL
were	NULL
not	NULL
receiving	NULL
oral	NULL
prednisone	NULL
maintenance	NULL
therapy	NULL
;	NULL
(	NULL
5	NULL
)	NULL
that	NULL
a	NULL
disease	NULL
control	NULL
group	NULL
receiving	NULL
chronic	NULL
high	NULL
dose	NULL
prednisone	NULL
therapy	NULL
did	NULL
not	NULL
show	NULL
the	NULL
same	NULL
degree	NULL
of	NULL
abnormality	NULL
in	NULL
GR	NULL
K	NULL
,	NULL
as	NULL
the	NULL
type	NULL
I	NULL
or	NULL
GR	NULL
number	NULL
as	NULL
the	NULL
type	NULL
II	NULL
SR	NULL
asthmatics	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
who	NULL
were	NULL
not	NULL
receiving	NULL
oral	NULL
prednisone	NULL
had	NULL
abnormal	NULL
GR	NULL
binding	NULL
affinity	NULL
in	NULL
the	NULL
same	NULL
range	NULL
as	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
receiving	NULL
oral	NULL
prednisone	NULL
maintenance	NULL
therapy	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
both	NULL
the	NULL
type	NULL
II	NULL
SR	NULL
asthmatics	NULL
were	NULL
studied	NULL
while	NULL
not	NULL
taking	NULL
systemic	NULL
glucocorti-coids	NULL
.	NULL

Finally	NULL
,	NULL
previous	NULL
studies	NULL
have	NULL
reported	NULL
that	NULL
glucocorticoid	NULL
treatment	NULL
induces	NULL
a	NULL
modest	NULL
downregulation	NULL
of	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
,	NULL
which	NULL
differs	NULL
from	NULL
the	NULL
alterations	NULL
seen	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
(	NULL
1	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
phenomenon	NULL
is	NULL
not	NULL
medication	NULL
induced	NULL
,	NULL
we	NULL
can	NULL
not	NULL
completely	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
previous	NULL
in	NULL
vivo	NULL
treatment	NULL
may	NULL
affect	NULL
the	NULL
GR	NULL
binding	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

The	NULL
SS	NULL
patients	NULL
also	NULL
have	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
as	NULL
compared	NULL
with	NULL
normal	NULL
donors	NULL
but	NULL
less	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
patients	NULL
.	NULL

These	NULL
data	NULL
are	NULL
of	NULL
particular	NULL
interest	NULL
because	NULL
they	NULL
suggest	NULL
that	NULL
chronic	NULL
asthma	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
a	NULL
spectrum	NULL
of	NULL
GR	NULL
binding	NULL
defects	NULL
with	NULL
SR	NULL
asthma	NULL
at	NULL
the	NULL
extreme	NULL
end	NULL
of	NULL
this	NULL
range	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
change	NULL
in	NULL
GR	NULL
binding	NULL
affinity	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
magnitude	NULL
of	NULL
airway	NULL
inflammation	NULL
.	NULL

This	NULL
phenomenon	NULL
along	NULL
with	NULL
the	NULL
possibility	NULL
of	NULL
irreversible	NULL
changes	NULL
in	NULL
the	NULL
airway	NULL
structure	NULL
could	NULL
explain	NULL
refractoriness	NULL
to	NULL
conventional	NULL
therapy	NULL
.	NULL

Although	NULL
not	NULL
specifically	NULL
ad-dressed	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
significantly	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
in	NULL
SS	NULL
asthma	NULL
patients	NULL
may	NULL
have	NULL
clinical	NULL
relevance	NULL
since	NULL
recent	NULL
studies	NULL
indicate	NULL
that	NULL
endogenous	NULL
cortisol	NULL
levels	NULL
regulate	NULL
IgE-dependent	NULL
late	NULL
phase	NULL
allergic	NULL
reactions	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Since	NULL
endogenous	NULL
cortisol	NULL
levels	NULL
are	NULL
significantly	NULL
lower	NULL
than	NULL
levels	NULL
achieved	NULL
after	NULL
the	NULL
administration	NULL
of	NULL
therapeutic	NULL
doses	NULL
of	NULL
steroids	NULL
,	NULL
even	NULL
the	NULL
moderate	NULL
abnormalities	NULL
in	NULL
GR	NULL
found	NULL
in	NULL
SS	NULL
asthmatics	NULL
may	NULL
have	NULL
an	NULL
influence	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
endogenous	NULL
glucocorticoids	NULL
to	NULL
suppress	NULL
airway	NULL
inflammation	NULL
.	NULL

Furthermore	NULL
,	NULL
even	NULL
modest	NULL
doses	NULL
of	NULL
inhaled	NULL
glucocorticoids	NULL
have	NULL
the	NULL
potential	NULL
to	NULL
reduce	NULL
Mechanisms	NULL
of	NULL
Steroid-resistant	NULL
Asthma	NULL
37	NULL
nocturnal	NULL
plasma	NULL
cortisol	NULL
concentrations	NULL
,	NULL
further	NULL
compromising	NULL
the	NULL
availability	NULL
of	NULL
endogenous	NULL
cortisol	NULL
during	NULL
the	NULL
critical	NULL
nighttime	NULL
period	NULL
when	NULL
pulmonary	NULL
function	NULL
is	NULL
lowest	NULL
in	NULL
patients	NULL
with	NULL
severe	NULL
asthma	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Consequently	NULL
,	NULL
inhaled	NULL
glucocorticoids	NULL
may	NULL
provide	NULL
symptomatic	NULL
relief	NULL
while	NULL
incompletely	NULL
resolving	NULL
the	NULL
inflammatory	NULL
process	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
understanding	NULL
of	NULL
the	NULL
mechanisms	NULL
which	NULL
underlie	NULL
SR	NULL
asthma	NULL
may	NULL
have	NULL
important	NULL
implications	NULL
for	NULL
controlling	NULL
inflammation	NULL
in	NULL
milder	NULL
forms	NULL
of	NULL
asthma	NULL
.	NULL

Since	NULL
there	NULL
is	NULL
only	NULL
one	NULL
GR	NULL
gene	NULL
,	NULL
our	NULL
observations	NULL
suggest	NULL
that	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
,	NULL
which	NULL
accounts	NULL
for	NULL
the	NULL
large	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
,	NULL
is	NULL
acquired	NULL
and	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
is	NULL
a	NULL
form	NULL
of	NULL
primary	NULL
cortisol	NULL
resistance	NULL
and	NULL
is	NULL
not	NULL
limited	NULL
to	NULL
T	NULL
cells	NULL
We	NULL
demonstrated	NULL
that	NULL
the	NULL
reduced	NULL
GR	NULL
binding	NULL
affinity	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
normal	NULL
PBMC	NULL
with	NULL
cytokines	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

This	NULL
raises	NULL
the	NULL
intriguing	NULL
hypothesis	NULL
that	NULL
SR	NULL
asthma	NULL
may	NULL
be	NULL
the	NULL
end	NULL
result	NULL
of	NULL
poorly	NULL
controlled	NULL
asthma	NULL
and	NULL
ongoing	NULL
immune	NULL
activation	NULL
.	NULL

It	NULL
has	NULL
been	NULL
previously	NULL
demonstrated	NULL
that	NULL
PHA-induced	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
by	NULL
PBMC	NULL
from	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
are	NULL
poorly	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
dexamethasone	NULL
or	NULL
methylprednisolone	NULL
in	NULL
vitro	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
however	NULL
,	NULL
we	NULL
reported	NULL
on	NULL
several	NULL
SR	NULL
patients	NULL
whose	NULL
asthma	NULL
came	NULL
under	NULL
control	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
troleandomycin	NULL
and	NULL
methylprednisolone	NULL
therapy	NULL
,	NULL
resulting	NULL
in	NULL
normalization	NULL
of	NULL
T	NULL
cell	NULL
sensitivity	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
methylprednisolone	NULL
on	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
cyclosporin	NULL
A	NULL
,	NULL
a	NULL
drug	NULL
whose	NULL
major	NULL
action	NULL
is	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
cytokine	NULL
secretion	NULL
,	NULL
was	NULL
reported	NULL
to	NULL
improve	NULL
the	NULL
clinical	NULL
symptoms	NULL
of	NULL
several	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
(	NULL
9	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
ongoing	NULL
asthma	NULL
inflammation	NULL
and	NULL
cytokine	NULL
secretion	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
acquired	NULL
GR	NULL
defect	NULL
found	NULL
in	NULL
type	NULL
I	NULL
SR	NULL
asthma	NULL
.	NULL

The	NULL
actual	NULL
mechanisms	NULL
by	NULL
which	NULL
cytokines	NULL
or	NULL
immune	NULL
activation	NULL
might	NULL
induce	NULL
a	NULL
decrease	NULL
in	NULL
GR	NULL
binding	NULL
affinity	NULL
are	NULL
unknown	NULL
.	NULL

One	NULL
possible	NULL
insight	NULL
may	NULL
relate	NULL
to	NULL
the	NULL
marked	NULL
difference	NULL
between	NULL
the	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
GR	NULL
binding	NULL
parameters	NULL
of	NULL
PBMC	NULL
from	NULL
SR	NULL
asthma	NULL
or	NULL
normal	NULL
PBMC	NULL
treated	NULL
with	NULL
combination	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
it	NULL
is	NULL
well	NULL
known	NULL
that	NULL
the	NULL
GR	NULL
changes	NULL
its	NULL
structure	NULL
and/or	NULL
conformation	NULL
when	NULL
translo-cated	NULL
between	NULL
the	NULL
nucleus	NULL
and	NULL
cytosol	NULL
.	NULL

At	NULL
a	NULL
cellular	NULL
level	NULL
,	NULL
glucocorticoids	NULL
exert	NULL
their	NULL
biological	NULL
effects	NULL
by	NULL
freely	NULL
penetrating	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
binding	NULL
to	NULL
a	NULL
specific	NULL
intracellular	NULL
receptor	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
the	NULL
GR	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
unli-ganded	NULL
receptor	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
heteromer	NULL
composed	NULL
of	NULL
a	NULL
single	NULL
steroid-	NULL
and	NULL
DNA-binding	NULL
subunit	NULL
and	NULL
two	NULL
90-kD	NULL
heat-shock	NULL
proteins	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
glucocorticoid	NULL
to	NULL
its	NULL
receptor	NULL
results	NULL
in	NULL
the	NULL
dissociation	NULL
of	NULL
the	NULL
90-kD	NULL
heat-shock	NULL
protein	NULL
sub-units	NULL
and	NULL
exposure	NULL
of	NULL
the	NULL
DNA-binding	NULL
site	NULL
on	NULL
the	NULL
receptor	NULL
.	NULL

This	NULL
activated	NULL
GR	NULL
complex	NULL
then	NULL
translocates	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
regulates	NULL
transcription	NULL
by	NULL
binding	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
called	NULL
glucocorticoid-responsive	NULL
elements	NULL
(	NULL
GRE	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
glucocorticoid-inducible	NULL
genes	NULL
which	NULL
have	NULL
been	NULL
identified	NULL
are	NULL
characterized	NULL
by	NULL
a	NULL
cluster	NULL
of	NULL
multiple	NULL
GREs	NULL
upstream	NULL
of	NULL
their	NULL
promoter	NULL
and	NULL
enhancer	NULL
regions	NULL
.	NULL

The	NULL
induction	NULL
or	NULL
repression	NULL
of	NULL
GR	NULL
target	NULL
genes	NULL
ultimately	NULL
results	NULL
in	NULL
the	NULL
altered	NULL
expression	NULL
of	NULL
glucocorticoid-regulated	NULL
proteins	NULL
(	NULL
21	NULL
)	NULL
.	NULL

This	NULL
latter	NULL
action	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
via	NULL
interaction	NULL
of	NULL
the	NULL
modulatory	NULL
domain	NULL
of	NULL
the	NULL
GR	NULL
with	NULL
transcriptional	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
activation	NULL
protein-1	NULL
(	NULL
AP-1	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
AP-1	NULL
interferes	NULL
with	NULL
the	NULL
function	NULL
of	NULL
the	NULL
modulatory	NULL
domain	NULL
of	NULL
the	NULL
GR	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Since	NULL
T	NULL
cells	NULL
from	NULL
SR	NULL
asthmatics	NULL
are	NULL
chronically	NULL
38	NULL
-	NULL
Sher	NULL
,	NULL
Leung	NULL
,	NULL
Surs	NULL
,	NULL
Kam	NULL
,	NULL
Zieg	NULL
,	NULL
Kamada	NULL
,	NULL
and	NULL
Szefler	NULL
activated	NULL
and	NULL
cytokines	NULL
can	NULL
induce	NULL
elevated	NULL
AP-1	NULL
levels	NULL
(	NULL
23	NULL
)	NULL
,	NULL
the	NULL
latter	NULL
observation	NULL
may	NULL
provide	NULL
a	NULL
plausible	NULL
explanation	NULL
for	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
the	NULL
GR	NULL
defect	NULL
in	NULL
SR	NULL
asthma	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
is	NULL
a	NULL
rare	NULL
,	NULL
but	NULL
well	NULL
described	NULL
syndrome	NULL
reported	NULL
in	NULL
humans	NULL
and	NULL
nonhuman	NULL
primates	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
clinical	NULL
syndrome	NULL
is	NULL
usually	NULL
familial	NULL
and	NULL
characterized	NULL
by	NULL
elevated	NULL
total	NULL
plasma	NULL
cortisol	NULL
concentrations	NULL
and	NULL
the	NULL
absence	NULL
of	NULL
signs	NULL
and	NULL
symptoms	NULL
of	NULL
Cushing	NULL
's	NULL
syndrome	NULL
.	NULL

The	NULL
mechanisms	NULL
for	NULL
end	NULL
organ	NULL
glucocorticoid	NULL
resistance	NULL
in	NULL
the	NULL
various	NULL
reported	NULL
kindreds	NULL
are	NULL
heterogenous	NULL
and	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
due	NULL
to	NULL
reduced	NULL
GR	NULL
number	NULL
,	NULL
decreased	NULL
binding	NULL
affinity	NULL
for	NULL
glucocorticoid	NULL
,	NULL
or	NULL
poor	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
GR	NULL
to	NULL
GRE	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
our	NULL
two	NULL
type	NULL
II	NULL
SR	NULL
asthma	NULL
patients	NULL
had	NULL
low	NULL
GR	NULL
number	NULL
that	NULL
was	NULL
not	NULL
restricted	NULL
to	NULL
their	NULL
T	NULL
cells	NULL
.	NULL

Clinically	NULL
,	NULL
one	NULL
of	NULL
these	NULL
patients	NULL
presented	NULL
many	NULL
features	NULL
consistent	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
including	NULL
the	NULL
abilities	NULL
to	NULL
maintain	NULL
normal	NULL
plasma	NULL
cortisol	NULL
concentrations	NULL
and	NULL
to	NULL
remain	NULL
free	NULL
of	NULL
glucocorticoid	NULL
adverse	NULL
effects	NULL
despite	NULL
daily	NULL
prednisone	NULL
therapy	NULL
in	NULL
doses	NULL
exceeding	NULL
20	NULL
mg/day	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
found	NULL
that	NULL
patients	NULL
with	NULL
SR	NULL
asthma	NULL
have	NULL
alterations	NULL
in	NULL
PBMC	NULL
GR	NULL
number	NULL
or	NULL
binding	NULL
affinity	NULL
.	NULL

With	NULL
the	NULL
increasing	NULL
use	NULL
of	NULL
systemic	NULL
steroids	NULL
to	NULL
treat	NULL
airway	NULL
inflammation	NULL
in	NULL
asthma	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
more	NULL
of	NULL
these	NULL
patients	NULL
will	NULL
be	NULL
identified	NULL
.	NULL

While	NULL
these	NULL
patients	NULL
may	NULL
respond	NULL
to	NULL
extremely	NULL
high	NULL
dose	NULL
glucocorticoid	NULL
therapy	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
identified	NULL
several	NULL
promising	NULL
treatment	NULL
regimens	NULL
as	NULL
alternatives	NULL
to	NULL
systemic	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

These	NULL
include	NULL
cyclosporin	NULL
,	NULL
troleando-mycin	NULL
,	NULL
methotrexate	NULL
,	NULL
gold	NULL
,	NULL
and	NULL
intravenous	NULL
gamma	NULL
globulin	NULL
therapy	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Characteristic	NULL
of	NULL
these	NULL
treatments	NULL
is	NULL
the	NULL
variable	NULL
response	NULL
observed	NULL
among	NULL
individual	NULL
patients	NULL
.	NULL

Our	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
variability	NULL
in	NULL
molecular	NULL
mechanisms	NULL
contributing	NULL
to	NULL
glucocorticoid	NULL
resistance	NULL
may	NULL
influence	NULL
response	NULL
to	NULL
therapeutic	NULL
intervention	NULL
.	NULL

Continued	NULL
research	NULL
is	NULL
needed	NULL
to	NULL
define	NULL
the	NULL
mechanisms	NULL
of	NULL
action	NULL
for	NULL
ongoing	NULL
immune	NULL
activation	NULL
and	NULL
the	NULL
correlation	NULL
to	NULL
response	NULL
to	NULL
individual	NULL
treatment	NULL
strategies	NULL
.	NULL

An	NULL
understanding	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
glucocorticoids	NULL
fail	NULL
to	NULL
resolve	NULL
inflammation	NULL
in	NULL
asthma	NULL
may	NULL
provide	NULL
important	NULL
insight	NULL
into	NULL
the	NULL
pathogenesis	NULL
of	NULL
asthma	NULL
,	NULL
especially	NULL
as	NULL
related	NULL
to	NULL
progressive	NULL
deterioration	NULL
,	NULL
and	NULL
may	NULL
result	NULL
in	NULL
the	NULL
rational	NULL
design	NULL
of	NULL
innovative	NULL
treatment	NULL
approaches	NULL
.	NULL

Acknowledgments	NULL
The	NULL
authors	NULL
thank	NULL
Drs	NULL
.	NULL

Allen	NULL
Adinoff	NULL
,	NULL
Lee	NULL
Newman	NULL
,	NULL
and	NULL
Talmadge	NULL
King	NULL
for	NULL
referring	NULL
patients	NULL
to	NULL
our	NULL
study	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Maureen	NULL
Plourd-Sandoval	NULL
for	NULL
assistance	NULL
in	NULL
preparing	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
U.	NULL
S.	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
HL-36577	NULL
and	NULL
AR-41256	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Wilson	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
R.	NULL
Djukanovic	NULL
,	NULL
P.	NULL
H.	NULL
Howarth	NULL
,	NULL
and	NULL
S.	NULL
T.	NULL
Holgate	NULL
.	NULL

1992	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
in	NULL
bronchoalveolar	NULL
lavage	NULL
and	NULL
peripheral	NULL
blood	NULL
in	NULL
atopic	NULL
asthma	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

145:958-960	NULL
.	NULL

2	NULL
.	NULL

Walker	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Bode	NULL
,	NULL
L.	NULL
Boer	NULL
,	NULL
T.	NULL
T.	NULL
Hansel	NULL
,	NULL
K.	NULL
Blaser	NULL
,	NULL
and	NULL
J.	NULL
Virchow	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

Allergic	NULL
and	NULL
nonallergic	NULL
asthmatics	NULL
have	NULL
distinct	NULL
patterns	NULL
of	NULL
T-cell	NULL
activation	NULL
and	NULL
cytokine	NULL
production	NULL
in	NULL
peripheral	NULL
blood	NULL
and	NULL
bronchoalveolar	NULL
lavage	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

146:109-115	NULL
.	NULL

3.	NULL
International	NULL
Consensus	NULL
Report	NULL
on	NULL
Diagnosis	NULL
and	NULL
Management	NULL
of	NULL
Asthma	NULL
.	NULL

U.	NULL
S.	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
,	NULL
Public	NULL
Health	NULL
Service	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Publication	NULL
No	NULL
.	NULL

92-3091	NULL
,	NULL
June	NULL
1992	NULL
.	NULL

4	NULL
.	NULL

Szefler	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
therapy	NULL
for	NULL
asthma	NULL
:	NULL
clinical	NULL
pharmacol-ogy	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

88:147-165	NULL
.	NULL

5	NULL
.	NULL

Schwartz	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
F.	NULL
C.	NULL
Lowell	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Melby	NULL
.	NULL

1968	NULL
.	NULL

Steroid	NULL
resistance	NULL
in	NULL
bronchial	NULL
asthma	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

69	NULL
(	NULL
3	NULL
)	NULL
:493-499	NULL
.	NULL

6	NULL
.	NULL

Carmichael	NULL
,	NULL
J.	NULL
,	NULL
I.	NULL
C.	NULL
Paterson	NULL
,	NULL
P.	NULL
Diaz	NULL
,	NULL
G.	NULL
K.	NULL
Crompton	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Kay	NULL
,	NULL
and	NULL
I.	NULL
W.	NULL
B	NULL
.	NULL

Grant	NULL
.	NULL

1981	NULL
.	NULL

Corticosteroid	NULL
resistance	NULL
in	NULL
chronic	NULL
asthma	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

282:1419-1422	NULL
.	NULL

7	NULL
.	NULL

Corrigan	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
P.	NULL
H.	NULL
Brown	NULL
,	NULL
N.	NULL
C.	NULL
Barnes	NULL
,	NULL
S.	NULL
J.	NULL
Szefler	NULL
,	NULL
J.-J	NULL
.	NULL

Tsai	NULL
,	NULL
A.	NULL
J.	NULL
Frew	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Kay	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
resistance	NULL
in	NULL
chronic	NULL
asthma	NULL
:	NULL
glucocorticoid	NULL
pharmacokinetics	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
characteristics	NULL
and	NULL
inhibition	NULL
of	NULL
peripheral	NULL
blood	NULL
T-cell	NULL
proliferation	NULL
by	NULL
glucocorticoid	NULL
in	NULL
vitro	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

144:1016-1025	NULL
.	NULL

8	NULL
.	NULL

Alvarez	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Surs	NULL
,	NULL
D.	NULL
Y.	NULL
M.	NULL
Leung	NULL
,	NULL
D.	NULL
Ikié	NULL
,	NULL
E.	NULL
W.	NULL
Gelfand	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Szefler	NULL
.	NULL

1992	NULL
.	NULL

Steroid	NULL
resistant	NULL
asthma	NULL
:	NULL
;	NULL
immunologic	NULL
and	NULL
pharmacologic	NULL
fea-tures	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

89:7	NULL
14-721	NULL
.	NULL

9	NULL
.	NULL

Corrigan	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
P.	NULL
H.	NULL
Brown	NULL
,	NULL
N.	NULL
C.	NULL
Barnes	NULL
,	NULL
J.-J	NULL
.	NULL

Tsai	NULL
,	NULL
A.	NULL
J.	NULL
Frew	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Kay	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
resistance	NULL
in	NULL
chronic	NULL
asthma	NULL
:	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocyte	NULL
activation	NULL
and	NULL
comparison	NULL
of	NULL
the	NULL
T	NULL
lymphocyte	NULL
inhibitory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

144:1026-1032	NULL
.	NULL

10	NULL
.	NULL

Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

,	NULL
J.	NULL
Caristedt-Duke	NULL
,	NULL
L.	NULL
Poellinger	NULL
,	NULL
S.	NULL
Okret	NULL
,	NULL
A.-C.	NULL
Wik-strom	NULL
,	NULL
M.	NULL
Bronnegiard	NULL
,	NULL
M.	NULL
Gillner	NULL
,	NULL
Y.	NULL
Dong	NULL
,	NULL
K.	NULL
Fuxe	NULL
,	NULL
A.	NULL
Cintra	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1987	NULL
.	NULL

Biochemistry	NULL
,	NULL
molecular	NULL
biology	NULL
,	NULL
and	NULL
physiology	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Endocr	NULL
.	NULL

Rev	NULL
.	NULL

§:185-234	NULL
.	NULL

11	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
B.	NULL
Mendel	NULL
,	NULL
L.	NULL
I.	NULL
Smith	NULL
,	NULL
and	NULL
E.	NULL
Orti	NULL
.	NULL

1990	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
and	NULL
actions	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

141	NULL
:	NULL
$	NULL
2-	NULL
$	NULL
10	NULL
.	NULL

12	NULL
.	NULL

American	NULL
Thoracic	NULL
Society	NULL
.	NULL

1987	NULL
.	NULL

Standards	NULL
for	NULL
the	NULL
diagnosis	NULL
and	NULL
care	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
obstructive	NULL
pulmonary	NULL
disease	NULL
(	NULL
COPD	NULL
)	NULL
and	NULL
asthma	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

136:225-244	NULL
.	NULL

13	NULL
.	NULL

Kamada	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
D.	NULL
Y.	NULL
M.	NULL
Leung	NULL
,	NULL
M.	NULL
C.	NULL
Gleason	NULL
,	NULL
M.	NULL
R.	NULL
Hill	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Szefler	NULL
.	NULL

1992	NULL
.	NULL

High-dose	NULL
systemic	NULL
glucocorticoid	NULL
therapy	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
asthma	NULL
:	NULL
a	NULL
case	NULL
of	NULL
resistance	NULL
and	NULL
patterns	NULL
of	NULL
response	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

90:68	NULL
5-687	NULL
.	NULL

14	NULL
.	NULL

Hill	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
S.	NULL
J.	NULL
Szefler	NULL
,	NULL
B.	NULL
D.	NULL
Ball	NULL
,	NULL
M.	NULL
Bartoszek	NULL
,	NULL
and	NULL
M.	NULL
Brenner	NULL
.	NULL

1990	NULL
.	NULL

Monitoring	NULL
glucocorticoid	NULL
therapy	NULL
:	NULL
a	NULL
pharmacokinetic	NULL
approach	NULL
.	NULL

Clin	NULL
.	NULL

Pharma-col.	NULL
&	NULL
Ther	NULL
.	NULL

48:390-398	NULL
.	NULL

15	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
K.	NULL
A.	NULL
Smith	NULL
,	NULL
and	NULL
A.	NULL
Munck	NULL
.	NULL

1981	NULL
.	NULL

Glucocorticoid	NULL
recep-tors	NULL
.	NULL

In	NULL
Methods	NULL
of	NULL
Hematology	NULL
.	NULL

Vol	NULL
.	NULL

2	NULL
.	NULL

The	NULL
Leukemic	NULL
Cell	NULL
.	NULL

D.	NULL
Catovsky	NULL
,	NULL
I.	NULL
Chanarin	NULL
,	NULL
E.	NULL
Beutler	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

Brown	NULL
,	NULL
and	NULL
A.	NULL
Jacobs	NULL
,	NULL
editors	NULL
.	NULL

Churchill	NULL
Livingstone	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

252-269	NULL
.	NULL

16	NULL
.	NULL

Robinson	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Q.	NULL
Hamid	NULL
,	NULL
S.	NULL
Ying	NULL
,	NULL
A.	NULL
Tsicopoulos	NULL
,	NULL
J.	NULL
Barkans	NULL
,	NULL
A.	NULL
M.	NULL
Bentley	NULL
,	NULL
C.	NULL
Corrigan	NULL
,	NULL
S.	NULL
R.	NULL
Durham	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Kay	NULL
.	NULL

1992	NULL
.	NULL

Predominant	NULL
T	NULL
;	NULL
,	NULL
;	NULL
-like	NULL
bronchoalveolar	NULL
T-lymphocyte	NULL
population	NULL
in	NULL
atopic	NULL
asthma	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

326:298-304	NULL
.	NULL

17	NULL
.	NULL

Kamada	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
D.	NULL
Y.	NULL
M.	NULL
Leung	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Szefler	NULL
.	NULL

1992	NULL
.	NULL

Steroid	NULL
resistance	NULL
in	NULL
asthma	NULL
:	NULL
our	NULL
current	NULL
understanding	NULL
.	NULL

Ped	NULL
.	NULL

Pulmonol	NULL
.	NULL

14:180-186	NULL
.	NULL

18	NULL
.	NULL

Herrscher	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
C.	NULL
Kasper	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Sullivan	NULL
.	NULL

1992	NULL
.	NULL

Endogenous	NULL
cortisol	NULL
regulates	NULL
immunoglobulin	NULL
E-dependent	NULL
late	NULL
phase	NULL
reactions	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

90:596-603	NULL
.	NULL

19	NULL
.	NULL

Law	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
J.	NULL
W.	NULL
Honour	NULL
,	NULL
J.	NULL
L.	NULL
Marchant	NULL
,	NULL
M.	NULL
A.	NULL
Preece	NULL
,	NULL
and	NULL
J.	NULL
O.	NULL
Warner	NULL
.	NULL

1986	NULL
.	NULL

Nocturnal	NULL
adrenal	NULL
suppression	NULL
in	NULL
asthmatic	NULL
children	NULL
taking	NULL
inhaled	NULL
beclomethasone	NULL
dipropionate	NULL
.	NULL

Lancer	NULL
.	NULL

1:942-944	NULL
.	NULL

20	NULL
.	NULL

Tabachnik	NULL
,	NULL
E..	NULL
and	NULL
Z.	NULL
Zadid	NULL
.	NULL

1991	NULL
.	NULL

Diurnal	NULL
cortisol	NULL
secretion	NULL
during	NULL
therapy	NULL
with	NULL
inhaled	NULL
beclomethasone	NULL
dipropionate	NULL
in	NULL
children	NULL
with	NULL
asthma	NULL
.	NULL

J.	NULL
Pediatr	NULL
.	NULL

118:294-297	NULL
.	NULL

21	NULL
.	NULL

Diamond	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
J.	NULL
N.	NULL
Miner	NULL
,	NULL
S.	NULL
K.	NULL
Yoshinaga	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
interactions	NULL
:	NULL
selectors	NULL
of	NULL
positive	NULL
or	NULL
negative	NULL
regulation	NULL
from	NULL
a	NULL
single	NULL
DNA	NULL
element	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
249:1266-1272	NULL
.	NULL

22	NULL
.	NULL

Yang-Yen	NULL
,	NULL
H.-F.	NULL
,	NULL
J.-C.	NULL
Chambard	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
J.	NULL
Schmidt	NULL
,	NULL
J.	NULL
Drouin	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
interference	NULL
between	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mutual	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
due	NULL
to	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Cel/	NULL
.	NULL

62:1205-1215	NULL
.	NULL

23	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

356:80	NULL
1-804	NULL
.	NULL

24	NULL
.	NULL

Brandon	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
A.	NULL
J.	NULL
Markwick	NULL
,	NULL
G.	NULL
P.	NULL
Chrousos	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Loriaux	NULL
.	NULL

1989	NULL
.	NULL

Glucocorticoid	NULL
resistance	NULL
in	NULL
humans	NULL
and	NULL
nonhuman	NULL
primates	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

49:2203-2213	NULL
.	NULL

25	NULL
.	NULL

Chrousos	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
A.	NULL
Vingerhoeds	NULL
,	NULL
D.	NULL
Brandon	NULL
,	NULL
C.	NULL
Eil	NULL
,	NULL
M.	NULL
Pugeat	NULL
,	NULL
M.	NULL
DeVroede	NULL
,	NULL
D.	NULL
L.	NULL
Loriaux	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Lipsett	NULL
.	NULL

1982	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
man	NULL
.	NULL

A	NULL
glucocorticoid	NULL
receptor-mediated	NULL
disease	NULL
.	NULL

J.	NULL
C/in	NULL
.	NULL

Invest	NULL
.	NULL

69	NULL
:	NULL
1261-1269	NULL
.	NULL

26	NULL
.	NULL

Hurley	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
D.	NULL
Accili	NULL
,	NULL
C.	NULL
A.	NULL
Stratakis	NULL
,	NULL
M.	NULL
Karl	NULL
,	NULL
N.	NULL
Vamvakopoulos	NULL
,	NULL
E.	NULL
Rorer	NULL
,	NULL
K.	NULL
Constantine	NULL
,	NULL
S.	NULL
I.	NULL
Taylor	NULL
,	NULL
and	NULL
G.	NULL
P.	NULL
Chrousos	NULL
.	NULL

1991	NULL
.	NULL

Point	NULL
mutation	NULL
causing	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
substitution	NULL
in	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
familial	NULL
glucocorticoid	NULL
resistance	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

87:680-686	NULL
.	NULL

27	NULL
.	NULL

Szefier	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

1992	NULL
.	NULL

Anti-inflammatory	NULL
therapy	NULL
in	NULL
allergic	NULL
disorders	NULL
.	NULL

Med	NULL
.	NULL

Clin	NULL
.	NULL

North	NULL
Am	NULL
.	NULL

76:953-975	NULL
.	NULL

Mechanisms	NULL
of	NULL
Steroid-resistant	NULL
Asthma	NULL
39	NULL

